GlassScriptPhysician profile
Jeffrey P Schultz
NPI 1063494763
$2,083.06
in general payments reported to CMS, 2019-2025
20 companies · $474 in 2025
The $474 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $86.47 · 2021: $90.81 · 2022: $171 · 2023: $327 · 2024: $436 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144 · Entertainment: $92.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.84 |
| Entertainment | $92.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $386.02 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $304.73 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $304.73 | 2019-2025 | Simbrinza, Dailies Total1, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.84 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $162.73 | 2023-2025 | Infuse, Miebo, Vyzulta |
| Samsara Vision | $126.68 | 2023-2024 | |
| Optos, INC. | $92.72 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $81.14 | 2019 | |
| Kala Pharmaceuticals, INC. | $77.43 | 2019 | |
| Sun Pharmaceutical Industries INC. | $64.62 | 2019 | |
| Coopervision INC. | $60.79 | 2025 | Misight Contact Lens |
| Harrow Eye, LLC | $60.43 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $56.01 | 2019-2023 | |
| Allergan, INC. | $46.59 | 2019 | |
| Glaukos Corporation | $27.69 | 2025 | Photrexa Viscous and Photrexa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $20.66 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $17.19 | 2022 | |
| Sight Sciences, INC. | $14.06 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.